- Home
- XTKG vs INDP Comparison
XTKG vs INDP Comparison
Compare XTKG & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- INDP
- Stock Information
- Founded
- XTKG 1997
- INDP 2000
- Country
- XTKG Singapore
- INDP United States
- Employees
- XTKG N/A
- INDP N/A
- Industry
- XTKG
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- XTKG
- INDP Health Care
- Exchange
- XTKG NYSE
- INDP Nasdaq
- Market Cap
- XTKG 8.5M
- INDP 8.8M
- IPO Year
- XTKG 2019
- INDP N/A
- Fundamental
- Price
- XTKG $1.14
- INDP $0.50
- Analyst Decision
- XTKG
- INDP Strong Buy
- Analyst Count
- XTKG 0
- INDP 2
- Target Price
- XTKG N/A
- INDP $8.50
- AVG Volume (30 Days)
- XTKG 194.5K
- INDP 1.2M
- Earning Date
- XTKG 05-21-2025
- INDP 03-13-2025
- Dividend Yield
- XTKG N/A
- INDP N/A
- EPS Growth
- XTKG N/A
- INDP N/A
- EPS
- XTKG N/A
- INDP N/A
- Revenue
- XTKG $15,234,138.00
- INDP N/A
- Revenue This Year
- XTKG N/A
- INDP N/A
- Revenue Next Year
- XTKG N/A
- INDP N/A
- P/E Ratio
- XTKG N/A
- INDP N/A
- Revenue Growth
- XTKG 51.59
- INDP N/A
- 52 Week Low
- XTKG $0.08
- INDP $0.47
- 52 Week High
- XTKG $2.14
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- XTKG 64.46
- INDP 24.26
- Support Level
- XTKG $1.07
- INDP $0.58
- Resistance Level
- XTKG $1.18
- INDP $0.78
- Average True Range (ATR)
- XTKG 0.13
- INDP 0.14
- MACD
- XTKG 0.01
- INDP -0.03
- Stochastic Oscillator
- XTKG 80.70
- INDP 1.89
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries that operates across four business segments: digital technologies, renewable energy, Cryptomining Operations, and agriculture technologies.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.